BIOMAT Database Logo BIOMAT Database Logo

Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database. 2018

Matthew S Karafin, and Matt Westlake, and Ronald G Hauser, and Christopher A Tormey, and Philip J Norris, and Nareg H Roubinian, and Yanyun Wu, and Darrell J Triulzi, and Steve Kleinman, and Jeanne E Hendrickson, and
Blood Center of Wisconsin, Milwaukee, WI, USA.

Despite the significance of red blood cell (RBC) alloimmunization, the lack of standardized registries in the US has prevented the completion of large studies. Data from 3·5 years of the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) recipient database, containing information from 12 hospitals, were studied. A RBC alloantibody responder had an antibody identified at any point during the study, and a non-responder had a negative antibody screen at least 15 days post-RBC transfusion. Demographics, blood type, ICD9/10 codes, and other potential correlates were evaluated. Of 319 177 (2·07%) screened patients, 6597 had a total of 8892 clinically significant RBC alloantibodies identified, with 75% being in the Rh or Kell families. Alloimmunization was more common in females (2·38%) than males (1·68%), and in RhD negative (2·82%) than RhD positive (1·94%) patients. Age, sex, RhD status and race were associated with being a responder, and certain diagnoses (including sickle cell disease or trait, systemic lupus erythematosus, rheumatoid arthritis and myelodysplastic syndrome) were more common among responders than non-responders. Data collected in this multi-centre recipient database provide the largest RBC alloimmunized patient cohort studied in the US, with previously known demographic and disease associations of responder status confirmed, and new associations identified.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007223 Infant A child between 1 and 23 months of age. Infants
D007518 Isoantibodies Antibodies from an individual that react with ISOANTIGENS of another individual of the same species. Alloantibodies
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009190 Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA. Dysmyelopoietic Syndromes,Hematopoetic Myelodysplasia,Dysmyelopoietic Syndrome,Hematopoetic Myelodysplasias,Myelodysplasia, Hematopoetic,Myelodysplasias, Hematopoetic,Myelodysplastic Syndrome,Syndrome, Dysmyelopoietic,Syndrome, Myelodysplastic,Syndromes, Dysmyelopoietic,Syndromes, Myelodysplastic
D001782 Blood Donors Individuals supplying blood or blood components for transfer to histocompatible recipients. Blood Donor,Donor, Blood,Donors, Blood
D001789 Blood Group Antigens Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties. Blood Group,Blood Group Antigen,Blood Groups,Antigen, Blood Group,Antigens, Blood Group,Group Antigen, Blood,Group, Blood,Groups, Blood
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children

Related Publications

Matthew S Karafin, and Matt Westlake, and Ronald G Hauser, and Christopher A Tormey, and Philip J Norris, and Nareg H Roubinian, and Yanyun Wu, and Darrell J Triulzi, and Steve Kleinman, and Jeanne E Hendrickson, and
Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III).
January 2019, Transfusion,
Matthew S Karafin, and Matt Westlake, and Ronald G Hauser, and Christopher A Tormey, and Philip J Norris, and Nareg H Roubinian, and Yanyun Wu, and Darrell J Triulzi, and Steve Kleinman, and Jeanne E Hendrickson, and
Blood donor, component, and recipient-specific factors associated with venous thromboembolism in transfused hospitalized adult patients: Data from the recipient epidemiology and donor evaluation Study-III (REDS-III).
May 2023, Transfusion,
Matthew S Karafin, and Matt Westlake, and Ronald G Hauser, and Christopher A Tormey, and Philip J Norris, and Nareg H Roubinian, and Yanyun Wu, and Darrell J Triulzi, and Steve Kleinman, and Jeanne E Hendrickson, and
The National Heart, Lung, and Blood Institute Recipient Epidemiology and Donor Evaluation Study (REDS-III): a research program striving to improve blood donor and transfusion recipient outcomes.
March 2014, Transfusion,
Matthew S Karafin, and Matt Westlake, and Ronald G Hauser, and Christopher A Tormey, and Philip J Norris, and Nareg H Roubinian, and Yanyun Wu, and Darrell J Triulzi, and Steve Kleinman, and Jeanne E Hendrickson, and
Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Study-III (REDS-III).
September 2021, Transfusion,
Matthew S Karafin, and Matt Westlake, and Ronald G Hauser, and Christopher A Tormey, and Philip J Norris, and Nareg H Roubinian, and Yanyun Wu, and Darrell J Triulzi, and Steve Kleinman, and Jeanne E Hendrickson, and
Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS)
March 2000, Hepatology (Baltimore, Md.),
Matthew S Karafin, and Matt Westlake, and Ronald G Hauser, and Christopher A Tormey, and Philip J Norris, and Nareg H Roubinian, and Yanyun Wu, and Darrell J Triulzi, and Steve Kleinman, and Jeanne E Hendrickson, and
Does recipient inflammation contribute to red blood cell alloimmunization?
June 2015, Transfusion,
Matthew S Karafin, and Matt Westlake, and Ronald G Hauser, and Christopher A Tormey, and Philip J Norris, and Nareg H Roubinian, and Yanyun Wu, and Darrell J Triulzi, and Steve Kleinman, and Jeanne E Hendrickson, and
Reticulocytes in donor blood units enhance red blood cell alloimmunization.
October 2023, Haematologica,
Matthew S Karafin, and Matt Westlake, and Ronald G Hauser, and Christopher A Tormey, and Philip J Norris, and Nareg H Roubinian, and Yanyun Wu, and Darrell J Triulzi, and Steve Kleinman, and Jeanne E Hendrickson, and
The Retrovirus Epidemiology Donor Study (REDS): rationale and methods.
January 1995, Transfusion,
Matthew S Karafin, and Matt Westlake, and Ronald G Hauser, and Christopher A Tormey, and Philip J Norris, and Nareg H Roubinian, and Yanyun Wu, and Darrell J Triulzi, and Steve Kleinman, and Jeanne E Hendrickson, and
The Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan.
May 2022, Transfusion,
Matthew S Karafin, and Matt Westlake, and Ronald G Hauser, and Christopher A Tormey, and Philip J Norris, and Nareg H Roubinian, and Yanyun Wu, and Darrell J Triulzi, and Steve Kleinman, and Jeanne E Hendrickson, and
Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.
July 2012, Blood,
Copied contents to your clipboard!